HBM Healthcare Investments AG - ESG Rating & Company Profile powered by AI
This analysis of HBM Healthcare Investments AG employs intelligence from across the internet and also from available filings by HBM Healthcare Investments AG. Check the end of the page for potential risks for HBM Healthcare Investments AG based on sector, location and size. The Disclosure score covers 17 UN SDGs including: 'Quality Education', 'Decent Work & Economic Growth' and 'Life below Water'.
HBM Healthcare Investments AG in the Biotechnology & Medical Research industry gained a UN SDG ESG Transparency Score of 5.1; made up of an environmental score of 6.7, social score of 4.6 and governance score of 4.0.
5.1
Medium ImpactEnvironmental
Social
Governance

Peer Group Comparison
Rank | Company | SDG Transparency Score ⓘ | Performance |
---|---|---|---|
1 | Analytik Jena AG | 8.0 | High |
1 | Amniotics AB (publ) | 8.0 | High |
60 | GDI Integrated Facility Services Inc | 5.2 | High |
60 | Aethlon Medical Inc | 5.2 | High |
62 | HBM Healthcare Investments AG | 5.1 | High |
63 | Keymed Biosciences Inc | 5.0 | High |
63 | Nightingale Health Oyj | 5.0 | High |
... | ... | ... | |
182 | Wesana Health Holdings Inc | 0.0 | Low |
182 | rEVO Biologics Inc | 0.0 | Low |
... | ... | ... |

Frequently Asked Questions
Does HBM Healthcare Investments AG have an accelerator or VC vehicle to help deliver innovation?
Does HBM Healthcare Investments AG disclose current and historical energy intensity?
Does HBM Healthcare Investments AG report the average age of the workforce?
Does HBM Healthcare Investments AG reference operational or capital allocation in relation to climate change?
Does HBM Healthcare Investments AG disclose its ethnicity pay gap?
Does HBM Healthcare Investments AG disclose cybersecurity risks?
Does HBM Healthcare Investments AG offer flexible work?
Does HBM Healthcare Investments AG have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Does HBM Healthcare Investments AG disclose the number of employees in R&D functions?
Does HBM Healthcare Investments AG conduct supply chain audits?
Does HBM Healthcare Investments AG disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Does HBM Healthcare Investments AG conduct 360 degree staff reviews?
Does HBM Healthcare Investments AG disclose the individual responsible for D&I?
Does HBM Healthcare Investments AG disclose current and historical air emissions?
Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Is executive remuneration linked to climate performance?
Does the Board describe its role in the oversight of climate-related risks and opportunities?
Does HBM Healthcare Investments AG disclose current and / or historical scope 2 emissions?
Does HBM Healthcare Investments AG disclose water use targets?
Does HBM Healthcare Investments AG have careers partnerships with academic institutions?
Did HBM Healthcare Investments AG have a product recall in the last two years?
Does HBM Healthcare Investments AG disclose incidents of discrimination?
Does HBM Healthcare Investments AG allow for Work Councils/Collective Agreements to be formed?
Has HBM Healthcare Investments AG issued a profit warning in the past 24 months?
Does HBM Healthcare Investments AG disclose parental leave metrics?
Does HBM Healthcare Investments AG disclose climate scenario or pathway analysis?
Does HBM Healthcare Investments AG disclose current and / or historical scope 1 emissions?
Are Operating Expesnses linked to emissions reduction?
Does HBM Healthcare Investments AG disclose the pay ratio of women to men?
Does HBM Healthcare Investments AG support suppliers with sustainability related research and development?
Does HBM Healthcare Investments AG disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Does HBM Healthcare Investments AG reflect climate-related risks in its financial statements?
Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Is HBM Healthcare Investments AG involved in embryonic stem cell research?
Does HBM Healthcare Investments AG disclose GHG and Air Emissions intensity?
Does HBM Healthcare Investments AG disclose its waste policy?
Does HBM Healthcare Investments AG report according to TCFD requirements?
Does HBM Healthcare Investments AG disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Does HBM Healthcare Investments AG disclose energy use targets?
Does HBM Healthcare Investments AG disclose its Renewable Energy targets?

Are emissions metrics verified by STBi?

Does HBM Healthcare Investments AG have a policy relating to cyber security?
Have a different question?
Potential Risks for HBM Healthcare Investments AG
These potential risks are based on the size, segment and geographies of the company.
HBM Healthcare Investments AG specializes in fund of funds and direct investments in middle market and mature companies. The fund prefers to invest in start up, early stage, mid stage, mid venture, late venture, and late stage private companies, unlisted emerging companies, small cap public companies, buyouts, growth capital, and private investment in public equities (PIPES). Within fund of funds, it invests in venture capital funds. It also seeks to finance spin-offs of product lines or departments from larger corporations and the expansion or restructuring of established companies, seed stages, venture capital, expansion capital stages, spin-offs, and buyouts. The fund prefers to invest in the private and public companies in the healthcare sector with a focus on human medicine, drugs, pharma , biopharma, biotechnology, diagnostics, medical technology, and related industries. It seeks to make initial investments in companies whose primary products are in clinical development or the immediately preceding stage. The fund typically invests globally with a focus on Asia Pacific, Asia, North America, and Europe. In case of public companies, it focuses on those which originate from its private portfolio. The fund increases its investment in portfolio companies by participating in a follow-on financing or after the portfolio company's IPO. It may acquire majority participations in portfolio companies, usually takes a seat on the portfolio company's Board of Directors, and largely makes equity investments but may also invest through other instruments including convertible bonds, debt securities, structured products, and derivatives. The fund exits its portfolio companies through trade sale or IPO.